Abstract
Objective. The Outcome Measures in Rheumatology (OMERACT) Filter provides guidelines for the development and validation of outcome measures for use in clinical research. The “Truth” section of the OMERACT Filter presupposes an explicit framework for identifying the relevant core outcomes that are universal to all studies of the effects of intervention effects. There is no published outline for instrument choice or development that is aimed at measuring outcome, was derived from broad consensus over its underlying philosophy, or includes a structured and documented critique. Therefore, a new proposal for defining core areas of measurement (“Filter 2.0 Core Areas of Measurement”) was presented at OMERACT 11 to explore areas of consensus and to consider whether already endorsed core outcome sets fit into this newly proposed framework.
Methods. Discussion groups critically reviewed the extent to which case studies of current OMERACT Working Groups complied with or negated the proposed framework, whether these observations had a more general application, and what issues remained to be resolved.
Results. Although there was broad acceptance of the framework in general, several important areas of construction, presentation, and clarity of the framework were questioned. The discussion groups and subsequent feedback highlighted 20 such issues.
Conclusion. These issues will require resolution to reach consensus on accepting the proposed Filter 2.0 framework of Core Areas as the basis for the selection of Core Outcome Domains and hence appropriate Core Outcome Sets for clinical trials.
- OUTCOME MEASURES IN RHEUMATOLOGY
- OUTCOME AND PROCESS ASSESSMENT
- CLINICAL TRIALS
- CONSENSUS DEVELOPMENT CONFERENCE
Footnotes
-
Dr. Matteson is supported in part by grants from Novartis, the American College of Rheumatology, and the European League Against Rheumatism; and was a consultant to Horizon Pharmaceuticals; Dr. Singh received research grants from Takeda and Savient, consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; is a member of the OMERACT executive, which receives arms-length funding from 36 companies; and is a member of the American College of Rheumatology’s Guidelines Subcommittee of the Quality of Care Committee and the Veterans Affairs Rheumatology Field Advisory Committee.
